Barinthus Biotherapeutics (BRNS) Stock: Buy, Sell, or Hold?
BRNS - Barinthus Biotherapeutics plc American Depositary Shares
$0.74
-0.02 (-2.49%)
âŧ
5d:
+6.18%
30d:
+23.56%
90d:
+2.79%
WAIT
LOW Confidence
Analysis Updated: Sep 8, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When BRNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BRNS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BRNS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: BRNS is currently trading at $0.74, which is considered fair based on recent price action.
Technical Outlook: Technically, BRNS is showing sideways momentum. Immediate support is located at $0.64, while resistance sits at $0.82.
Market Sentiment: BRNS scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+710.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BRNS is showing sideways momentum. Immediate support is located at $0.64, while resistance sits at $0.82.
Market Sentiment: BRNS scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+710.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
32/100
(SELL)
Volume Confirmation
UNKNOWN
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (0/100)
- BULLISH: Trading 710.7% below Wall St target ($6.00)
- WARNING: Composite score 32/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$0.64
Resistance Level
$0.82
Current Trend
Sideways
Technical data as of
Sep 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.65
Wall Street Target
$6.00
(+710.7%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 14, 2026 1:39 AM ET
Data refreshes hourly during market hours. Next update: 2:39 AM
Data refreshes hourly during market hours. Next update: 2:39 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BRNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 58 HOLD |
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
29 analysts |
$371 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
20 analysts |
$306 | 52 HOLD |
|
PVLA
Palvella Therapeutics, IâĻ |
STRONG BUY
15 analysts |
$231 | 67 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$75 | 65 BUY |
